Orforglipron for Fat Loss
First oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.
Why Orforglipron for fat loss?
Orforglipron (LY3502970) is Eli Lilly's small-molecule, non-peptide GLP-1R agonist. Unlike oral semaglutide it does not require SNAC absorption enhancers or fasted dosing. Phase 2 obesity (2023) showed up to 14.7% weight loss at 36 weeks. Phase 3 ATTAIN and ACHIEVE programs read out in 2025.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Orforglipron fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Weight loss comparable to injectable GLP-1s in Phase 2
Reference dosing by bodyweight
Anchored to the most-cited research dose (12000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 7480–10120 mcg |
| 60–75 kg / 132–165 lb | 9180–12420 mcg |
| 75–90 kg / 165–198 lb | 11220–15180 mcg |
| 90–105 kg / 198–231 lb | 13260–17940 mcg |
| >105 kg / >231 lb | 15300–20700 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Vomiting
- Diarrhea
- Constipation
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.